Heart Test Laboratories ("HTL") is pleased to announce it has added new key management team members as it prepares to launch the MyoVista to the market. Andrew Simpson has been appointed Executive Chairman and Mark Hilz has been appointed CEO. They join HTL to lead the company as it transitions from a development company to a full service medical device business with manufacturing and sales operations.
Mr Simpson and Mr Hilz are both investors in the company and will both serve on the HTL board.
Satisfied Users & 
Approved Press Releases
